EU/3/18/2095
Table of contents
About
On 19 November 2018, orphan designation (EU/3/18/2095) was granted by the European Commission to United Neuroscience Limited, Ireland, for Ile-Ser-Ile-Thr-Glu-Ile-Lys-Gly-Val-Ile-Val-His-Arg-Ile-Glu-Thr-Ile-Leu-Phe-Lys-Lys-Lys-Lys-Glu-Met-Pro-Ser-Glu-Glu-Gly-Tyr-Gln-Asp (also known as UB-312) for the treatment of multiple system atrophy.
The sponsor’s address was updated in May 2020.
Key facts
Active substance |
Ile-Ser-Ile-Thr-Glu-Ile-Lys-Gly-Val-Ile-Val-His-Arg-Ile-Glu-Thr-Ile-Leu-Phe-Lys-Lys-Lys-Lys-Glu-Met-Pro-Ser-Glu-Glu-Gly-Tyr-Gln-Asp
|
Disease / condition |
Treatment of multiple system atrophy
|
Date of first decision |
19/11/2018
|
Outcome |
Positive
|
EU designation number |
EU/3/18/2095
|
Review of designation
The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.
Sponsor's contact details
United Neuroscience Limited
International Financial Services Centre
9 Exchange Place
I.f.s.c.
Dublin 1
Co. Dublin
Ireland
Tel. +353 (0)15175929
E-mail: info@unitedneuroscience.com
Patients' organisations
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.